🔗 Share this article

As America undertakes historic changes to its vaccine guidelines, a particular individual has emerged in a surprising turn: Dr. Tracy Beth Høeg, a US-based physician and public health researcher who first made her name by questioning coronavirus vaccines during the pandemic and has zeroed in on possible deaths after COVID-19 vaccination in her short position at the Food and Drug Administration.

Scheduled Shifts to Childhood Vaccine Schedule

Health officials planned to announce major revisions to the childhood vaccine schedule in December, aligning the US with Denmark’s national calendar, sources say – a major change that would place the US out of step with a large portion of the international standard with no evidence for public health gain. The planned update has been pushed back until the coming year.

Rather than the top vaccines chief, Høeg is listed to present at the meeting. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the center this calendar year.

Consolidating Power at the Regulatory Body

The acting appointment could signify a closer partnership between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it points to a renewed priority upon rolling back long-standing vaccines at the FDA.

The new acting director has often pushed for halting certain pediatric immunization guidelines in the US to become more like the Danish model, a country with comprehensive healthcare and a citizenry about the population of the state of Wisconsin.

In her initial comments, she has continued to focus on vaccines – typically the purview of Dr. Prasad, chief of the FDA’s CBER – instead of medication approval.

Doubts Over Expertise

Høeg has no apparent background in medication creation, regulation or management, which has been standard for former directors of the CBER. She has been employed at the FDA as a top consultant to the commissioner and the vaccine center since spring.

“She appears not to have any of the qualifications” for running the CDER, said Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in leading a major agency. She lacks background in drug approvals.”

Former commissioners of CBER would “be deeply familiar with regulatory frameworks and the science of drug development”, noted a former acting FDA commissioner. “Frankly, she lacks the sort of resume that previous people who led the center have had.”

This division has an enormous portfolio at the agency, she emphasized.

“Many people just focuses on the novel medication approvals, but the generic drug division approves numerous off-brand pharmaceuticals. There’s a biosimilars division, non-prescription drug unit and more, and all of those must be supervised,” Woodcock noted. “The thing you neglect, that is precisely what that I always told people is going to bite you.”

There is also, a significant leadership element to the position, which oversees in excess of 5,000 employees. “It is a enormous administrative position, if you perform it correctly,” she said.

Response and Disputed Policies

In response to questions about Dr. Høeg's qualifications and whether this selection indicates greater collaboration among agency officials on immunizations, a representative responded that the “concerns are based on flawed premises”.

“Her resume matches the duties of her role,” the spokesperson stated, citing the period Høeg spent counseling the agency head on “drug safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg inherits the commissioner’s recently launched fast-track approval initiative, a contentious expedited therapy clearance system that reportedly troubled her preceding directors. “How are these therapies being chosen for this fast-track system? Who makes the calls?” Dr. Howard asked. “There is a lot of lack of transparency going on at the agency right now.”

Overall, he remarked, “the Food and Drug Administration appears to be shifting towards less stringent oversight of most medications, with the exception of immunizations.”

Established History on Vaccines

Regarding immunizations, Dr. Høeg has a more established, if problematic, track record, some experts have noted. She authored a study using unconfirmed volunteer-provided data to determine the frequency of heart inflammation following COVID-19 vaccination. She advised the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have altered data to indicate COVID-19 vaccinations are more dangerous than they are.

Included in her “desired changes” for the new federal leadership included changing regulations for new vaccines and ending “non-essential” immunizations, she said after the election on a podcast. At the agency, Dr. Høeg has allegedly suggested preventing young men from obtaining Covid vaccines.

“She’s an all-around dogmatist who commences with her preconceived notions and reverse-engineers to fit the data in a very misleading, dishonest way,” Howard said.

Consolidating Power and a “Revenge Tour”

Høeg became part of other dissenters, {like|